PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes

April 21, 2025, Yantai -- The Phase 3 trial results of Boan Biotech’s BA5101 (Dulagutide Injection, formerly code-named LY05008) were recently published in Journal of Diabetes.BA5101 is a biosim...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025

Boan Biotech Announces 2024 Financial Results

* Strong growth of RMB 190 million in net profit* Time to reap the benefits of R&DBoan Biotech (6955.HK) today announced its annual results for fiscal year 2024 and latest developments.In the repo...

PROPOSED APPOINTMENTS OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

Boan Biotech's CD228 ADC Granted ODD by US FDA

Boan Biotech announced that its BA1302, a novel CD228-directed antibody drug conjugate (ADC), has recently been granted the Orphan Drug Designations (ODD) for the treatment of squamous non-small-cell ...

BA1302 GRANTED ODD FOR SQNSCLC AND PANCREATIC CANCER BY U.S. FDA

Boan Holds BPD Type 2b Meeting with FDA on BA1104

Boan Biotech announced that regarding its self-developed BA1104 (Nivolumab Injection), the company has held a Biological Product Development (BPD) type 2b meeting with the U.S. Food and Drug Administr...

NOTICE OF BOARD MEETING